Retatrutide: The Triple-Agonist GLP-1/GIP/GCG (2026 Update)

Retatrutide is the most-watched compound in the obesity-pharmacology pipeline as of mid-2026. It is not approved. It is not available through legitimate prescribing channels for obesity. The compounded preparations that have circulated in some peptide markets are not a substitute for the approved branded product, which does not yet exist. None of that has dampened the interest, because the phase 2 data is the most striking weight-loss readout the GLP-1 class has produced to date.

This article walks through what retatrutide actually is, what makes triple-agonism mechanistically different from current options, what the phase 2 numbers look like, what to expect from phase 3, and where a responsible telehealth provider stands on the question of when to offer it.

What retatrutide is

Retatrutide is a once-weekly subcutaneous peptide developed by Eli Lilly. It is an agonist at three receptors:

1. The GLP-1 receptor — the same target as semaglutide, liraglutide, and the GLP-1 component of tirzepatide. GLP-1 agonism slows gastric emptying, reduces appetite via central pathways, and improves glycemic control.
2. The GIP receptor — the same target as the GIP component of tirzepatide. GIP agonism contributes to glycemic control and, in combination with GLP-1, appears to enhance both weight loss and tolerability relative to GLP-1 alone.
3. The glucagon receptor (GCG) — the new addition. Glucagon agonism is the mechanistic difference between retatrutide and tirzepatide. Activating the glucagon receptor in the liver and peripheral tissue raises basal energy expenditure — the body burns more energy at rest — and contributes to lipid mobilization. Glucagon agonism for weight loss is a mechanism that has been pursued for decades; retatrutide is the first triple-agonist to advance into late-stage clinical development with data that suggests the trade-offs (primarily on heart rate and glycemic control) can be managed in clinical use.

Triple-agonism is not just additive. The mechanism stacks complementary effects: GLP-1 reduces input (appetite, food consumed), GIP supports the metabolic context, and glucagon increases output (energy expenditure). This combination, in principle, addresses both sides of the energy-balance equation in a way that single- or dual-receptor agonists do not.¹

How the mechanism compares to current GLP-1s

For prescribers and patients, the practical question is what triple-agonism means relative to the current options. Here is a clean comparison:

• Semaglutide (GLP-1 mono-agonist). Appetite suppression, slowed gastric emptying, glycemic control. Mean weight loss in phase 3 (STEP 1): −14.9% at 68 weeks at the 2.4 mg target dose.²
• Tirzepatide (GLP-1 + GIP dual agonist). Same GLP-1 effects, with GIP-mediated improvements in glycemic control and tolerability. Mean weight loss in phase 3 (SURMOUNT-1): −20.9% at 72 weeks at the 15 mg target dose.³
• Retatrutide (GLP-1 + GIP + GCG triple agonist). All of the above, plus glucagon-mediated increases in basal energy expenditure. Mean weight loss in phase 2 at 48 weeks at the highest dose: approximately −24.2%, with the curve not yet clearly plateauing at trial end.⁴

The phase 2 number is striking, but it is a phase 2 number. Phase 2 trials are smaller, the population is more selected, and the eventual phase 3 figure could be lower in real-world use. The relevant point is the trajectory: the slope of the dose-response curve and the time-to-plateau both look favorable for retatrutide relative to existing options.

The phase 2 readout, in numbers

The retatrutide phase 2 obesity trial enrolled adults with a BMI of 30 or higher (or 27-29.9 with at least one weight-related comorbidity) and randomized them across multiple dose arms versus placebo. Key results:

• At 24 weeks: mean body-weight reduction of approximately −17.5% at the 12 mg dose, versus −2.0% with placebo.
• At 48 weeks: mean body-weight reduction of approximately −24.2% at the 12 mg dose, versus −2.1% with placebo.
• Dose-response: monotonic across the tested range, with higher doses producing larger weight reductions and no clear ceiling within the doses tested.
• Placebo arm: weight reduction tracked the typical placebo response in obesity pharmacotherapy trials with concurrent lifestyle intervention.

The 48-week curve at the highest dose was still descending at trial end, which is the most-discussed feature of the readout. In SURMOUNT-1, the tirzepatide curve had largely plateaued by 72 weeks. If the retatrutide curve continues to descend through phase 3 follow-up, the eventual maximal mean weight reduction could exceed the phase 2 number — though projections beyond available data are projections.

Side effect profile, with the caveats

The reported tolerability profile in phase 2 was qualitatively similar to other GLP-1-class agents, with gastrointestinal events dominating:

• Nausea, vomiting, diarrhea. Mostly mild-to-moderate, concentrated in the dose-escalation phase, declining as patients reached maintenance dose. Rates were broadly comparable to tirzepatide at similar dose-equivalent points.
• Heart-rate increase. Mean increases of approximately 5-7 beats per minute at higher doses. This is the glucagon-receptor signal — glucagon agonism is known to raise heart rate — and is the variable that phase 3 cardiovascular safety monitoring will scrutinize most closely.
• Glycemic effects in non-diabetics. Glucagon agonism counteracts some of the glycemic benefit of GLP-1/GIP agonism. In diabetic patients this is being managed; in non-diabetic patients on retatrutide for weight loss alone, fasting glucose changes have been minor but require monitoring.
• Discontinuation rates. Phase 2 discontinuations due to adverse events were higher than placebo and broadly in line with what would be expected for a GLP-1-class agent at the doses tested. Phase 3 will produce the definitive numbers.

The cardiovascular signal in particular is the variable that will determine the eventual label. If phase 3 shows a heart-rate increase that is sustained but clinically benign in the trial population, the label will likely require monitoring but not exclusion. If phase 3 surfaces a cardiovascular safety signal beyond the heart-rate increase, the label could be restricted or the development program affected.

Where regulatory approval stands

As of mid-2026, retatrutide is in active phase 3 development under the TRIUMPH program (obesity) and parallel programs in type 2 diabetes. Topline results from the largest obesity readouts are expected through 2026 and into 2027. FDA approval for an obesity indication has not occurred and is not expected before late 2026 at the earliest, with most analysts modeling 2027 as the more realistic timeline.

This matters because compounded retatrutide has appeared in some peptide channels, marketed as an early-access option for patients who want to skip the approval timeline. That is not how legitimate compounding works. Compounded preparations under 503A are made in response to individual prescriptions for medications where there is a clinical justification and where the active pharmaceutical ingredient meets quality standards. Retatrutide as a research peptide is not an approved active pharmaceutical ingredient. Compounded retatrutide marketed for weight loss in 2026 should be regarded as a research-grade product being sold for clinical use, not a legitimate compounded medication.

When responsible telehealth providers will offer it

The honest answer is: after FDA approval, and after the approved branded product is available through legitimate pharmacy channels.

Several reasons, in plain terms:

1. The safety dataset is incomplete. Phase 2 is enough to justify continued development. It is not enough to justify general clinical use. The cardiovascular monitoring picture in particular needs phase 3 data.
2. The compounded route is not legitimate. Prescribing a research-grade peptide as a compounded medication for an indication where an approved product is in the regulatory pipeline does not pass clinical or legal scrutiny. Providers who do this are taking on risk that legitimate operators will not.
3. Patients have effective alternatives. Patients who would benefit from triple-agonism today are, in nearly every case, candidates for tirzepatide or semaglutide at appropriate doses. Real-world tirzepatide outcomes are excellent for the patient population that would otherwise be candidates for retatrutide.

TelePeptide will offer retatrutide once it is FDA-approved for an indication that fits the patient, once the branded product is available through legitimate pharmacy channels, and once the clinical team has reviewed the approved label. None of those conditions are met as of this writing.

What this means for patients asking about retatrutide

If you are an existing GLP-1 patient: stay on what is working. The marginal benefit of switching from a well-tolerated, effective tirzepatide protocol to an unapproved alternative is not the trade-off it appears to be from a phase 2 weight-loss number alone.

If you are considering starting GLP-1 therapy: start with what is approved, available, and clinically supported. Tirzepatide and semaglutide produce substantial weight loss for the patients who are appropriate candidates, and their long-term safety datasets are the largest in the class.

If you are watching the pipeline because retatrutide-class effect sizes interest you: that is a reasonable thing to track. The honest expectation is that retatrutide reaches a US obesity label between late 2026 and 2027, and that legitimate prescribing follows shortly after. A telehealth provider that promises sooner access through compounding is signaling something other than clinical conservatism.

Where TelePeptide stands

TelePeptide does not currently offer retatrutide. It will not be offered as a compounded preparation. It will be added to the formulary after FDA approval, after supply through approved pharmacy channels is established, and after clinical-team review of the approved labeling. Patients interested in being notified when that happens can request to be added to the clinical update list at intake.

These statements have not been evaluated by the FDA. Compounded medications are not FDA-approved. Prescribing decisions are made solely by licensed clinicians based on individual medical necessity.

Footnotes

1. Coskun T, Urva S, Roell WC, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism 34(9): 1234–1247. ↩

2. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384, 989–1002. DOI:10.1056/NEJMoa2032183. ↩

3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387, 205–216. DOI:10.1056/NEJMoa2206038. ↩

4. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine 389, 514–526. DOI:10.1056/NEJMoa2301972. ↩